Deciphera Pharmaceuticals, Inc. (DCPH) Forms $24.54 Double Bottom; SLC AGRICOLA S A (SLCJY) Sellers Increased By 8825% Their Shorts

January 13, 2018 - By Marie Mckinney

SLC AGRICOLA S A (OTCMKTS:SLCJY) had an increase of 8825% in short interest. SLCJY’s SI was 35,700 shares in January as released by FINRA. Its up 8825% from 400 shares previously. With 10,900 avg volume, 3 days are for SLC AGRICOLA S A (OTCMKTS:SLCJY)’s short sellers to cover SLCJY’s short positions. The stock increased 0.84% or $0.075 during the last trading session, reaching $9.015. About 16,800 shares traded. SLC Agrícola S.A. (OTCMKTS:SLCJY) has 0.00% since January 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Deciphera Pharmaceuticals, Inc. (DCPH) formed double bottom with $23.80 target or 3.00% below today’s $24.54 share price. Deciphera Pharmaceuticals, Inc. (DCPH) has $799.80M valuation. The stock decreased 1.80% or $0.45 during the last trading session, reaching $24.54. About 224,160 shares traded or 23.51% up from the average. Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) has 0.00% since January 13, 2017 and is . It has underperformed by 16.70% the S&P500.

SLC Agrícola S.A. produces and sells agricultural products in Brazil and internationally. The company has market cap of $915.19 million. The firm operates through two divisions, Agricultural Production and Land Investments. It has a 8.5 P/E ratio. The Company’s products include soybean, corn, cotton, wheat, sunflower, sugarcane, ethanol, and corn seeds.

Analysts await Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) to report earnings on February, 13. After $-5.85 actual EPS reported by Deciphera Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -92.99% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Marie Mckinney







Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: